Drug intelligence / Profile preview

DHNP-2025

Development stage: Preclinical
Lead developer: Daehan Nupharm
Modality: Small Molecules
Administration: Oral

Overview

DHNP-2025 is a small molecule therapeutic candidate being developed by Daehan Nupharm for the treatment of diabetes. According to the company's pipeline, the asset is currently in the formulation stage of development. While specific details regarding its molecular target or mechanism of action have not been publicly disclosed, it represents part of Daehan Nupharm's internal research and development efforts to expand its metabolic disease portfolio.

Beyond the preview

Go deeper on DHNP-2025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHNP-2025.

Explore the full profile